Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We're optimistic about this one |
| Our earning launch trajectory of ROLVEDON has provided a very positive end to the year and the momentum has continued to build throughout the first quarter of 2023 |
| We've executed our launch strategy, and established a strong foundation |
| As we move into 2023, we are well positioned to continue investing in the launch trajectory and lifecycle management of the product while maintaining a very disciplined and lean operating structure |
| It's been a very exciting quarter |
| These are significant accomplishments for the brand and speak to the urgency and capability of our team |
| We believe the unique features of ROLVEDON, combined with the current market dynamics, offer our team an opportunity to grow appropriate utilization and solidify ROLVEDON's position in the market |
| As a result, our strategy centers around a provider focus that delivers both short and long-term predictable value, which creates a great foundation for early adoption and continued growth |
| So I think the team is executing quite well |
| But all the measures that we're seeing whether it be the ones that we shared today on NCCN and the J-Code, or the continued breadth and depth of our utilization are kind of fueling our excitement and our team's energy as they're out engaging with customers |
| The fourth quarter of 2022 was the first quarter ROLVEDON was commercially available, and we are pleased with the early reception from our customers |
| The optimism within the company is certainly fuelled by the launch of ROLVEDON |
| Erin has extensive growth factor experience, has been on oncology for over 20 years and the Spectrum is fortunate to have her leading the charge |
| That number has more than doubled in the first quarter, and the breadth of overall users continues to accelerate |
| So I think from our perspective, one, seeing the early customer receptivity with the sales we recorded in the fourth quarter, despite the hurdle of the miscellaneous J-Code I think it fuels our enthusiasm for customer receptivity |
| This gives us greater flexibility on pricing and contracting, which allows us to offer customers much needed visibility to make short and long-term business decisions |
| On the heels of a strong launch quarter, and EDSM [Ph] is high at the company and with our customers, and we're looking forward to the future |
| we are focused and really pleased with what we're seeing with what we have in the bag, and that is our non-inferiority label, given 24 hours post chemo |
| This was an important milestone for the product, and it will be very welcomed by our current customers, and also remove barriers to utilization with potential new customers |
| Additionally, we're in the process of contracting with our first hospital IBM System and anticipate expanded utilization across all segments |
| For instance, in the first quarter, we've been able to expand utilization across specialty distribution networks and group purchasing organizations |
| To set a solid foundation for an oncology launch, it's important to see the largest customers being receptive to the product, along with a systematic increase in breadth of overall users |
| Our team is motivated by the opportunities in front of us, and it understands the importance of sustained success over time |
| So I think the reason we wanted to share that particular metric, it's one we really value and look at internally, because to be successful, for the long-term goals, you have to increase the breadth of utilization, both intra customer and intra segment and across segments for that matter |
| But I think the lead driver that's going to -- that's going to be the place of greatest success early indicators are that's going to be in the community followed by 340B |
| Both commercially and through lifecycle management with our same day dosing study and to further differentiate the brand |
| Moving forward, our plan is to continue to increase utilization in the clinic space while also capitalizing on opportunities within the hospital segment |
| I think a big accomplishment for the brand was achieving that J-Code in the time because I think that's the important measure here |
| The combination of financial discipline and maximizing ROLVEDON’s launch will allow us to begin to realize our broader strategic vision |
| Unidentified Analyst Excellent, thanks so much, and congratulations on all the progress |
| Statement |
|---|
| I think there's other practical strategic challenges that one faces |
| I think those are going to be a challenge |
| One challenge we've encountered since approval is the fact that ROLVEDON claims are currently submitted with a miscellaneous J-Code |
| But is there anything that took place in the fourth quarter that that might be might have impacted the revenues obviously, in a positive way that we might not see in subsequent quarters |
| The decrease was due to lower program activities for ROLVEDON |
| But I don't think we have delusions of grandeur of the challenge that we're going to face in that segment |
| There are 113 systems representing 50% of long acting G-CSF sales and we knew that our experience navigating those systems would allow us to connect quickly and pull through early sales |
| In a market with tremendous price instability, providers appreciate visibility |
| So customers who engaged with the product who have started using the product and aspire to use it in a deeper concentration of their business, but it may have had a hurdle with one of their predominant payers |
| Net loss from continuing operations was $11.7 million or $0.06 per share for the quarter ended December 31, 2022 compared to a net loss from continuing operations of $39.8 million or $0.26 per share for the comparable period in 2021 |
| What we've learned from that engagement is there will be payers that we will not do business with, because our strategic interests are not aligned |
| And I think that will that will shrink over time |
| And I guess two related questions |
| Given the consolidation of many of the community clinics that have been have become hospitals over the years I think that thinking has infiltrated many of the large IDN systems |
Please consider a small donation if you think this website provides you with relevant information